Information  X 
Enter a valid email address

PureTech Health PLC (PRTC)

  Print   

Thursday 19 May, 2022

PureTech Health PLC

PDMR Notification RSU Vesting

RNS Number : 0232M
PureTech Health PLC
19 May 2022
 

19 May 2022

PureTech Health plc

 

PDMR Notifications

 

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, announces that awards of restricted share units ("RSUs") granted by PureTech on 20 December 2019 to certain directors and other persons discharging managerial responsibilities ("PDMRs") pursuant to its Performance Share Plan ("PSP")  vested at 95.8% on 3 February 2022 following satisfaction of performance conditions measured over the three year period to 31 December 2021. In addition, certain RSUs granted to George Farmer, PureTech's Chief Financial Officer, pursuant to its PSP vested in full on 1 January 2022 in accordance with a time-based vesting schedule. 

Each PDMR received vested ordinary shares (after deduction of shares for payroll taxes) on 18 May 2022. The market price per ordinary share in the Company used to calculate the amount payable to the PDMRs and the amount of shares to be issued to PDMRs was 175 pence, being the average closing price of the Company's shares over the three trading day period immediately preceding the settlement, and the exchange rate used to calculate the cash payment and amount of share settlement was £1:$1.2359.

The Company's total issued ordinary share capital is 288,611,159 shares after the share issuance to the PDMRs.

PDMR Notification

 

The information contained in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.

1

Details of the person discharging managerial responsibilities/person closely associated

a)

Name

Daphne Zohar

Bharatt Chowrira

Eric Elenko

Joseph Bolen

George Farmer

 

2

Reason for the notification

a)

Position/status

Daphne Zohar - Chief Executive Officer

Bharatt Chowrira - President and Chief Business, Legal and Operating Officer

Eric Elenko - Chief Innovation and Strategy Officer

Joseph Bolen - Chief Scientific Officer

George Farmer - Chief Financial Officer

b)

Initial notification/Amendment

Initial Notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

PureTech Health plc

b)

LEI

213800LVPDNO2Z9T9I39

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary Shares of PureTech Health plc

ISIN GB00BY2Z0H74


b)

Nature of the transaction

Issuance of ordinary shares in net settlement of certain vested RSUs under the PureTech Health Performance Share Plan, after retentions in respect of payroll taxes.

c)

Price(s) and volume(s)

Recipient

Price

Amount

Daphne Zohar

0.01 GBP

366,882 ordinary shares

Bharatt Chowrira

0.01 GBP

69,600 ordinary shares

Eric Elenko

0.01 GBP

127,476 ordinary shares

Joseph Bolen

0.01 GBP

127,476 ordinary shares

George Farmer

0.01 GBP

18,282 ordinary shares

d)

Aggregated information

-

Aggregated volume

-

Price

Price

Aggregate Volume

0.01 GBP

709,717 ordinary shares

e)

Date of the transaction

18 May 2022

f)

Place of the transaction

London Stock Exchange (XLON)

 

About PureTech Health 

PureTech is a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic and immunological conditions, intractable cancers, lymphatic and gastrointestinal diseases and neurological and neuropsychological disorders, among others. The Company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders.

This pipeline, which is being advanced both internally and through PureTech's Founded Entities, is comprised of 27 therapeutics and therapeutic candidates, including two that have received both U.S. FDA clearance and European marketing authorization, as of the date of PureTech's most recently filed Annual Report and corresponding Form 6-K. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on unique insights in immunology and drug development.

For more information, visit www.puretechhealth.com or connect with us on Twitter @puretechh.

Contact:

PureTech

Investor Relations

[email protected]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGPUBWAUPPGBR

a d v e r t i s e m e n t